Citadel Advisors
BCYC

Citadel Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Citadel Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.6K Buy
19,300
+5,900
+44% +$33.7K ﹤0.01% 12105
2025
Q4 		$94.9K Buy
+13,400
New +$98.8K ﹤0.01% 11688
2025
Q2 		– Sell
-27,700
Closed -$235K – 12566
2025
Q1 		$235K Buy
27,700
+21,100
+320% +$249K ﹤0.01% 10124
2024
Q4 		$92.4K Buy
6,600
+500
+8% +$10.7K ﹤0.01% 11595
2024
Q3 		$138K Buy
6,100
+3,600
+144% +$83K ﹤0.01% 10677
2024
Q2 		$50.6K Sell
2,500
-9,100
-78% -$206K ﹤0.01% 11746
2024
Q1 		$289K Sell
11,600
-4,500
-28% -$95.6K ﹤0.01% 9525
2023
Q4 		$291K Sell
16,100
-13,900
-46% -$230K ﹤0.01% 9222
2023
Q3 		$603K Buy
30,000
+2,200
+8% +$50.3K ﹤0.01% 7655
2023
Q2 		$709K Buy
27,800
+800
+3% +$18.6K ﹤0.01% 7170
2023
Q1 		$574K Buy
27,000
+4,800
+22% +$120K ﹤0.01% 8037
2022
Q4 		$657K Buy
+22,200
New +$596K ﹤0.01% 7680
2022
Q3 		– Sell
-10,400
Closed -$175K – 12607
2022
Q2 		$175K Sell
10,400
-900
-8% -$19K ﹤0.01% 10840
2022
Q1 		$496K Sell
11,300
-300
-3% -$14K ﹤0.01% 9419
2021
Q4 		$706K Buy
11,600
+6,500
+127% +$359K ﹤0.01% 8814
2021
Q3 		$212K Buy
+5,100
New +$178K ﹤0.01% 11866

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's BCYC Position: Q1 2026 in Review

Citadel Advisors increased its Bicycle Therapeutics (BCYC) stake by 39% in Q1 2026, buying an estimated $604K and bringing the position to 377,085 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #6374.

Citadel Advisors first reported a position in BCYC in Q4 2020 and has held it in 19 quarters since. The position peaked at $5.32M in Q4 2023. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Citadel Advisors held 377,085 shares of Bicycle Therapeutics worth $1.75M as of Q1 2026.
  • Citadel Advisors bought 105,702 Bicycle Therapeutics shares in Q1 2026, an estimated $604K.
  • Bicycle Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6374 holding.
  • Citadel Advisors first reported a position in Bicycle Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Bicycle Therapeutics position peaked at $5.32M in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.